EIGR Eiger BioPharmaceuticals Inc.

11.03
-2  -15%
Previous Close 13.03
Open 11.5
Price To Book 3.19
Market Cap 212442686
Shares 19,260,443
Volume 1,272,883
Short Ratio
Av. Daily Volume 73,394

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released October 16, 2018 - endpoints met. Data presented at ENDO March 25, 2019.
Avexitide (Exendin 9-39)
Post-Bariatric Hypoglycemia (PBH)
Phase 2 LIMT data noted 36% curable virologic response at 24 weeks post-treatment - April 11. 2019.
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
Phase 3 enrolment to be completed by the end of 2019.
Lonafarnib - D-LIVR
Chronic hepatitis delta virus (HDV)
Phase 2 trial did not meet endpoints - January 16, 2018.
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2 data released October 16, 2018 did not meet endpoints.
Ubenimex - ULTRA
Secondary lymphedema
Phase 2b negative data released April 2015. Formerly CLDN pre-merger
MYDICAR - CUPID 2 Trial
Ischemic or dilated cardiomyopathy
Phase 2 data to be presented at AASLD November 8-12, 2019.
Pegylated interferon lambda + ritonavir (RTV)-boosted lonafarnib (LNF) - LIFT
Hepatitis delta virus (HDV)
NDA filing 2019.
Lonafarnib
Hutchinson-Gilford Progeria Syndrome (HGPS)

Latest News

  1. Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
  2. Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
  3. Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors
  4. Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
  5. Eiger BioPharmaceuticals to Participate in Conferences in April
  6. Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
  7. Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019
  8. What Makes Eiger BioPharma (EIGR) a New Buy Stock
  9. Eiger BioPharma: 4Q Earnings Snapshot
  10. Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019
  11. Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit
  12. [$$] Five Best: Susan Froderberg on Extraordinary Mountain Ascents
  13. Clinigen and Eiger BioPharmaceuticals Launch Worldwide Managed Access Program for Lonafarnib for Patients with Progeria and Progeroid Laminopathies
  14. Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer
  15. Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
  16. Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
  17. Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors
  18. Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?
  19. Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies